These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 21642014

  • 21. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
    Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ.
    Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
    [Abstract] [Full Text] [Related]

  • 22. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 23. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May 15; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 24. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
    Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB.
    Ann Rheum Dis; 2014 Dec 15; 73(12):2174-7. PubMed ID: 24972708
    [Abstract] [Full Text] [Related]

  • 25. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK.
    J Rheumatol; 2014 Apr 15; 41(4):648-57. PubMed ID: 24584918
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
    Tun GS, Lobo AJ.
    Expert Opin Drug Metab Toxicol; 2015 Feb 15; 11(2):317-27. PubMed ID: 25586216
    [Abstract] [Full Text] [Related]

  • 27. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 15; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 28. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D.
    Health Technol Assess; 2010 Oct 15; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [Abstract] [Full Text] [Related]

  • 29. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.
    Gastroenterology; 2006 Feb 15; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [Abstract] [Full Text] [Related]

  • 30. A review and expert opinion of the use of certolizumab for Crohn's disease.
    Evans AT, Lee SD.
    Expert Opin Biol Ther; 2012 Mar 15; 12(3):363-70. PubMed ID: 22339409
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
    Feagan BG, Hanauer SB, Coteur G, Schreiber S.
    Aliment Pharmacol Ther; 2011 May 15; 33(10):1143-51. PubMed ID: 21443536
    [Abstract] [Full Text] [Related]

  • 32. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, Staelens F, Koetse W, Bertin P.
    Arthritis Care Res (Hoboken); 2015 Feb 15; 67(2):151-60. PubMed ID: 25302624
    [Abstract] [Full Text] [Related]

  • 33. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
    Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lémann M, Colombel JF.
    Aliment Pharmacol Ther; 2010 Jan 15; 31(1):92-101. PubMed ID: 19709098
    [Abstract] [Full Text] [Related]

  • 34. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.
    Gastroenterology; 2007 Jan 15; 132(1):52-65. PubMed ID: 17241859
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
    Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P, Swiss IBDnet.
    Inflamm Bowel Dis; 2011 Jul 15; 17(7):1530-9. PubMed ID: 21674709
    [Abstract] [Full Text] [Related]

  • 36. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
    Baker DE.
    Rev Gastroenterol Disord; 2008 Jul 15; 8(4):240-53. PubMed ID: 19107098
    [Abstract] [Full Text] [Related]

  • 37. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
    Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN, CDP870 Crohn's Disease Study Group.
    Int J Colorectal Dis; 2008 Mar 15; 23(3):289-96. PubMed ID: 18071721
    [Abstract] [Full Text] [Related]

  • 38. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
    Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M.
    Arthritis Rheum; 2011 Aug 15; 63(8):2203-8. PubMed ID: 21484766
    [Abstract] [Full Text] [Related]

  • 39. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
    Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P.
    Clin Gastroenterol Hepatol; 2010 Aug 15; 8(8):688-695.e2. PubMed ID: 20451663
    [Abstract] [Full Text] [Related]

  • 40. Certolizumab pegol in the treatment of Crohn's disease.
    Ferrante M, Vermeire S, Rutgeerts P.
    Expert Opin Biol Ther; 2013 Apr 15; 13(4):595-605. PubMed ID: 23451881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.